BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study

BACKGROUND: Trials of the Pfizer-BioNTech BNT162b2 mRNA vaccine showed 95% efficacy in preventing symptomatic disease; however, the trials excluded immunocompromised patients (ICPs). We aim at analyzing antibody response in ICPs. METHODS: A prospective cohort study was conducted at Sheba Medical Cen...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahav, Galia, Lustig, Yaniv, Lavee, Jacob, Ohad Benjamini, Magen, Hila, Hod, Tammy, Noga Shem-Tov, Shmueli, Einat Shacham, Drorit Merkel, Ben-Ari, Ziv, Halperin, Rebecca, Indenbaum, Victoria, Olmer, Liraz, Huppert, Amit, Mor, Eytan, Regev-Yochay, Gili, Cohen, Carmit, Finesod, Anat Wieder-, Levy, Itzchak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520708/
https://www.ncbi.nlm.nih.gov/pubmed/34693234
http://dx.doi.org/10.1016/j.eclinm.2021.101158

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520708/
https://www.ncbi.nlm.nih.gov/pubmed/34693234
http://dx.doi.org/10.1016/j.eclinm.2021.101158

Ejemplares similares